These studies, conducted in three independent cohorts, have found that TMEM number is prognostic for increased risk of metastatic disease in early stage breast cancer (EBC), including ER-positive and HER2-negative disease [4,5,7]. This evidence concerns the gene ERBB2 and metastatic neoplasm.